Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.
0/5 보강
APA
Lee KW, Zang DY, et al. (2025). Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.. British journal of cancer, 133(2), 274. https://doi.org/10.1038/s41416-025-03092-4
MLA
Lee KW, et al.. "Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.." British journal of cancer, vol. 133, no. 2, 2025, pp. 274.
PMID
40542173
같은 제1저자의 인용 많은 논문 (3)
- Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma.
- Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.
- Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.